This site is intended only for healthcare professionals resident in the United Kingdom
Besponsa® Clinical Papers
Use the links below to access Besponsa® clinical papers
1. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukaemia; Kantarjian HM et al. NEJM 2016; 375: 740-753
This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-INO-GBR-0370. March 2020
2. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review; Kebriaei P, et al. Bone Marrow Transplant 2018;53:449–456
This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-INO-GBR-0369. March 2020
3. Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment; Marks DI et al. Cancer Medicine. 2019;8 :5959-5968.
This clinical paper has been certified by Pfizer Ltd. in accordance with the ABPI Code of Practice and contains promotional information and is intended for UK Healthcare Professionals. PP-INO-GBR-0365. March 2020
PP-INO-GBR-0290. May 2020
Prescribing information
BESPONSA® (inotuzumab ozogamicin) 1 mg powder for concentrate for solution for infusion
Legal category: Prescription only medicine. Cost: £8,048 per vial.
Click here to access the BESPONSA Summary of Product Characteristics hosted on Datapharm’s ‘electronic Medicines Compendium’.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
Cytarabine 20 mg/mL and 100 mg/mL solution for infusion or injection
Legal category: Prescription only medicine. Basic NHS price: Cytarabine 100 mg/mL, supplied as single vials containing 100 mg/mL cytarabine in 10 mL (1 g), £39.00 or 20 mL (2 g), £77.50. Cytarabine 20 mg/mL supplied as vials containing 20 mg/mL cytarabine in 5 mL (100 mg) in packs of 5, £20.48 or 25 mL (500 mg) as single vials, £19.50.
Click here to access the cytarabine 20 mg/mL and click here to access the cytarabine 100 mg/mL Summary of Product Characteristics hosted on Datapharm’s ‘electronic Medicines Compendium’.
Developments in Leukaemia Care video
Clinical papers
